This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (69) Citing Articles via Google Scholar Google Scholar Articles by Wiviott, S. D. Search for Related Content PubMed PubMed Citation Articles by Wiviott, S. D.

Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy

A PROVE IT-TIMI 22 Substudy

Stephen D. Wiviott, MD^_*,,_*, Christopher P. Cannon, MD, FACC^_*,, David A. Morrow, MD, MPH, FACC^_*,, Kausik K. Ray, MD, Marc A. Pfeffer, MD, PhD, FACC^_*, Eugene Braunwald, MD, MACC^_*, for the PROVE IT-TIMI 22 Investigators

^_* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
The TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts

View larger version (17K): [in a new window]   Figure 1 Distribution of four-month calculated low-density lipoprotein (LDL) (mg/dl) levels among subjects treated with intensive statin therapy (atorvastatin, 80 mg).

View larger version (13K): [in a new window]   Figure 2 Hazard ratio of the primary end point compared with achieved calculated low-density lipoprotein (LDL) 80 to 100 mg/dl (adjusted for age, gender, baseline calculated low-density lipoprotein, diabetes mellitus, and prior myocardial infarction).